High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial
Clinical Infectious Diseases2009Vol. 49(9), pp. 1441–1449
Citations Over TimeTop 1% of 2009 papers
Yazdan Yazdanpanah, Catherine Fagard, Diane Descamps, Anne Marie Taburet, Céline Colin, Bénédicte Roquebert, Christine Katlama, Gilles Pialoux, Christine Jacomet, Christophe Piketty, Diane Bollens, Jean‐Michel Molina, Geneviève Chêne
Abstract
In patients infected with multidrug-resistant virus who have few remaining treatment options, the combination of raltegravir, etravirine, and darunavir/ritonavir is well tolerated and is associated with a rate of virologic suppression similar to that expected in treatment-naive patients.
Related Papers
- → Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients(2012)36 cited
- → Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States(2010)25 cited
- → Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients(2010)21 cited
- → Salvage Regimens Containing Darunavir, Etravirine, Raltegravir, or Enfuvirtide in Highly Treatment-Experienced Perinatally Infected Pregnant Women(2013)10 cited
- → Darunavir + Raltegravir + Etravirine = High Rate of Treatment Success(2009)